1-17 of 17
Keywords: Biologics
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Journal Articles
Journal: Dermatology
Dermatology (2021) 237 (4): 658–672.
Published Online: 13 January 2021
... from any ideas, methods, instructions or products referred to in the content or advertisements. Alopecia Alopecia areata Inflammatory bowel disease Crohn’s disease Ulcerative colitis Biologics Scarring alopecia Research Article Dermatology 2021;237:658 671 DOI: 10.1159/000512747 Received...
Journal Articles
Journal: Dermatology
Dermatology (2020) 236 (5): 413–420.
Published Online: 14 January 2020
... (83.9%), topical antibiotic therapy (74.5%), metabolic medications such as metformin/zinc (67.1%), intralesional Kenalog (63.1%), and biologic therapies (tumor necrosis factor-α inhibitors; TNF-α inhibitors; 49%). In examining the response rate, patients with disease localized to the buttocks had...
Journal Articles
Journal Articles
Journal Articles
Journal: Dermatology
Dermatology (2016) 232 (3): 326–333.
Published Online: 20 April 2016
...Der Yi Hsu; Robert Gniadecki Background: Low adherence to therapies in psoriasis decreases treatment outcomes and increases the total health care costs. In spite of the wide use of biologic agents, patients' adherence to these drugs has not been extensively investigated. Objective: The aim...
Journal Articles
Journal Articles
Journal: Dermatology
Dermatology (2014) 229 (4): 324–332.
Published Online: 15 November 2014
..., instructions or products referred to in the content or advertisements. Psoriasis Biologics Tumor necrosis factor-α inhibitor Ustekinumab Clinical trials Real life Psoriasis is a common, lifelong immune-mediated skin disease affecting 0.5-4.6% of the world's population, with an equal sex...
Journal Articles
Journal: Dermatology
Dermatology (2012) 224 (3): 236–243.
Published Online: 01 June 2012
... for the network in several round table meetings. Results: Eight out of 10 registries had a prospective comparator cohort with similar disease characteristics but not on biologics. Registries differed in the coding and validation or follow-up of adverse events and in the way they sampled their population. Fifteen...
Journal Articles
Journal: Dermatology
Dermatology (2012) 224 (3): 228–230.
Published Online: 09 March 2012
...A.G.A. Kolios; F. Rusca; K. Reisenbauer; A. Cozzio; L.E. French; A.A. Navarini Background: Biologics are used increasingly to treat moderate-to-severe psoriasis. Here the topical treatment habits (corticosteroids and vitamin D derivates) and moisturizer use of 97 Swiss patients (male 65, female 32...
Journal Articles
Journal: Dermatology
Dermatology (2011) 222 (2): 119–122.
Published Online: 22 January 2011
... a risk factor for developing HZ. Anti-HZ vaccination prior to ustekinumab treatment should be considered. Biologics Anti-IL-12/23 Anti-p40 Varicella zoster virus Herpes zoster 12 12 2010 21 12 2010 22 1 2011 © 2011 S. Karger AG, Basel 2011 Copyright / Drug Dosage...
Journal Articles
Journal: Dermatology
Dermatology (2010) 221 (Suppl. 1): 29–42.
Published Online: 09 August 2010
.... The current management of nail psoriasis includes topical, intralesional and systemic therapies, although little clinical evidence is available on the effectiveness of conventional treatments and, consequently, no specific treatment approach has been fully supported. Biologic agents are beginning to emerge...
Journal Articles
Journal: Dermatology
Dermatology (2009) 219 (4): 353–356.
Published Online: 23 October 2009
...N. Irla; N. Yawalkar Background: Nail involvement is known as a common finding in psoriatic patients and represents a significant impact on patients’ quality of life. The treatment of nail psoriasis is often challenging, and there is a need for new therapeutic options. Biologicals effective...
Journal Articles
Journal: Dermatology
Dermatology (2009) 219 (3): 209–218.
Published Online: 05 August 2009
... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Biologics Meta-analysis Psoriasis Randomized controlled trial...
Journal Articles
Journal: Dermatology
Dermatology (2008) 216 (4): 355–360.
Published Online: 20 February 2008
... to in the content or advertisements. Biologics Etanercept Pustular psoriasis Tumor necrosis factor α Generalized pustular psoriasis (GPP) is a severe and disabling variant of psoriasis, characterized by recurrent, sterile, pustular eruptions. This unusual manifestation most commonly recognizes...
Journal Articles
Journal: Dermatology
Dermatology (2008) 216 (2): 171–172.
Published Online: 23 January 2008
...C. Barde; A.M. Thielen; J.-H. Saurat Background: In a previous paper we described 2 patients treated with a sequential biologic therapy for chronic plaque psoriasis. We used infliximab as an induction treatment followed by efalizumab. We extended this approach to 3 other patients. Objective...
Journal Articles
Journal: Dermatology
Dermatology (2007) 215 (1): 72–75.
Published Online: 21 June 2007
...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Biologics TNF-alpha inhibitors Infliximab Psoriasis vulgaris Pityriasis rubra pilaris Treatment with so-called...